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THE DEVELOPMENT OF SHEEP EXPRESSING 
GROWTH PROMOTING TRANSGENES
The first successful attempts to transfer foreign DNA into mice (Gordone, 
et al, 1980) were rapidly followed by a number of reports demonstrating 
that foreign DNA, or transgenes, can be permanently incorporated into 
an animal’s genome (Costantini and Lacy, 1981; E. Wagner, et al, 1981; T.
Wagner, et al., 1981). Once incorporated, 
transgenes are stable and can be transmitted to 
an animal’s progeny in the course of normal 
breeding.
The potential for the application of transgenic 
technology to alter animals used in agriculture 
was further indicated by Palmiter and his col-
leagues (1982,1983). These workers produced 
mice transgenic with a rat growth hormone 
(rGH) gene that was under the control of the 
mouse metallothionein I (MT) gene promoter, 
thus directing the production of GH in the liver 
rather than the anterior pituitary. The resulting transgenic mice that ex-
pressed this transgene grew to approximately 1.5 to 2 times as large as 
non-transgenic littermates. Thus, they established that the alteration of the 
pattern of expression of a gene, or the expression of a foreign gene, could 
result in a marked change in a quantitative trait like body growth. The 
control of growth, feed efficiency, reproduction, fat deposition and dis-
ease resistance are all economically important traits in animal agriculture.
At this point in 1982, laboratories at the USDA/ARS facility at Beltsville, 
Maryland (C.E.R. Jr.) and the CSIRO, Division of Animal Production in 
Sydney, Australia (J.D.M.) began experiments designed to transfer growth 
hormone transgenes into sheep. The goals of both groups were to deter-
mine 1—if growth hormone transgenic sheep were more feed efficient, i.e., 
produced more muscle per unit of food consumed, 2-contained less fat 
and 3-grew more rapidly than non-transgenic controls, as such modifica-
tions would be advantageous to producers. In this paper we will discuss 
the experimental work concerned with producing growth hormone trans-
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genic sheep leading to the present, as well as our thoughts on the ethical 
and social considerations of this work.
ETHICAL IMPLICATIONS
Should we use genetic engineering? A frequently asked question is “Do we 
have the right to change the genetics of a species?” and each member of 
these research teams had to answer that question to his, or her, own satis-
faction. As agricultural and basic research scientists, we realized that this 
question had already been answered thousands of years ago. Soon after 
mankind first domesticated plants and animals selective breeding began 
to be practiced, thus leading to man-made changes in the genomes of all 
domesticated species.
Wild cattle were bred to become Herefords, Angus and Holsteins. The 
original domesticated wild dogs have been selected for different purposes 
and bred until today there are a multitude of breeds. All of our domesti-
cated animals, both those used in agriculture and the companion species, 
are now represented by a wide variety of breeds or types. The same is true 
for plants, although for plants mankind has gone much further. Using 
currently acceptable breeding techniques plant breeders have already pro-
duced entirely new species, such as the grain triticale, for use in agriculture.
Traditional breeding techniques rely on hybridization between breeds 
or species to yield genetic variation upon which we can impose selective 
breeding to fix desirable gene combinations. Essentially this involves ma-
nipulating and introducing changes into an animal’s entire genome, con-
taining perhaps as many as a hundred thousand genes. By comparison, ge-
netic engineering involves introducing one or two characterized genes 
into one animal and assessing the effect of the expression of that gene on 
that animal and its immediate progeny. Thus, to us, transgenic technology 
is a more precise extension of the genetic manipulations characterized by 
selective breeding which farmers and agricultural scientists commonly 
practice.
TECHNICAL DEVELOPMENTS
Gene transfer in mice had been achieved by microinjecting a DNA con-
taining solution directly into one of the two pronuclei of the zygote (for 
technical details see Hogan, et a\., 1986). In the mouse the optimal time for 
collecting pronuclear embryos suitable for microinjection is approxi-
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mately 15 hours after fertilization. Following microinjection, mouse em-
bryos are transferred immediately back into the oviduct of pseudopreg-
nant females. Alternatively, microinjected mouse embryos can be cultured 
overnight to the two-cell stage and then transferred into a recipient.
Superovulation protocols were well worked out for the production and 
collection of sheep embryos around seven or eight days old, but protocols 
had to be developed for the collection of fertilized sheep eggs at the pro- 
nuclear stage. The techniques required for the transfer of day six to eight 
blastocysts to a recipient ewe’s uterus were established, but again there was 
a need to develop the most optimal protocol for the transfer of day one 
embryos. Lastly, sheep zygotes had not previously been studied to deter-
mine if pronuclei were visible during the one-cell stage or, if they were vis-
ible, at what time were they optimum for microinjection. Thus, when 
work was started to produce the first transgenic sheep, there was consider-
able background information which needed to be established empirically 
before standardized protocols could be established.
The first transgenic sheep was reported in 1985 by Hammer, e t al. This 
single animal demonstrated that it was at least possible to transfer a for-
eign gene, in this case a mouse metallothionein human growth hormone 
(mMThGH) fusion gene, into sheep albeit at a very low efficiency. To date 
there are reports in the literature from three groups that have successfully, 
and routinely, produced transgenic sheep resulting in sheep carrying nine 
different transgenes (Table 1). However, as reviewed by Rexroad and 
Pursel (1988) the efficiency of producing genetically engineered sheep is 
still low, with only about 0.75 to 1 percent of the microinjected eggs trans-
ferred into recipient ewes resulting in the birth of transgenic lambs. An 
even lower percentage of embryos transferred result in lambs expressing 
the incorporated transgene, as not all transgenic animals express the new 
gene.
To reach this point essentially required a better understanding of the 
timing of the early development of the sheep embryo, rather than new 
technological breakthroughs. A treatment step requiring the administra-
tion of gonadotropin releasing hormone (GnRH) to the superovulation 
protocol was added to ensure that ovulation in the donor ewes was more 
nearly synchronous, thus greatly increasing the number of fertilized eggs 
collected at the pronuclear stage (Nancarrow, et al, 1984). Centrifugation
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Table 1. E f f i c i e n c y  o f  p r o d u c t i o n  o f  t r a n s g e n i c  s h e e p
Number of Transgenic
injected lambs
embryos Lambs Lambs expressing
Transgene transferred born transgenic* Number %
mMT-hGH* 1032 73 1 — —
mMT-bGH* 842 47 2 2 IOO
mMT-hGRF* 435 63 9 1/7 14
mMT-bGH* M7 42 11 3 27
mAL-hGRF* 171 16 4 2 50
mMT-Tkb 150 29 1 — —
BLG-FIXb 307 52 4 2/2 IOO
BLG-alpha lATh 49 11 1 1 IOO
Mtla-oGH5‘ 1089 83 4 0 0
Mtla-oGH9‘ 409 23 3 3 IOO
Totals 3699 439 (n.8) 40 (l.l) 14 35
■ Rcxroad, et al., 1990.
mMT = mouse metallotheionein 1
mTF = mouse transferrin
mAL = mouse albumin
hGH = human growth hormone
bGH = bovine growth hormone
hGRF = human GH releasing factor
kSimons, et al, 1988
BLG = ovine beta-lactoglobulin
Tk = thymidine kinase
FIX = human blood clotting factor IX
alpha iAT=human alpha i-antitrypsin
‘Murray, etal, 1989
Mtla = ovine metallothionein ta
oGH = ovine growth hormone
Mtla-oGHs transgene incorporated SV40 viral enhancer sequences, while the Mtla-oGH9 
construct did not.
* Nancarrow, etal., (1991) have since produced 1 additional transgenic sheep with each of 
the Mtla-oGH constructs, with the Mtla-pGH9 individual expressing the transgene. 
However, the numbers of injected embryos transferred and number of lambs born were 
not reported.
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of the zygotes was tried to improve the visualization of the pronuclei 
(Nancarrow, etal, 1984), but in contrast to pig embryos (Wall, etal, 1985) 
this was not helpful. Suitable visualization of pronuclei in sheep zygotes 
can be obtained by the critical use of differential interference contrast 
optics, whereby over 90 percent of pronuclear stage eggs can be suc-
cessfully microinjected (Simons, etal, 1988; Murray, etal, 1989; 
Rexroad, et al., 1989).
Part of the inefficiency in the production of transgenic farm animals re-
sults from imperfect handling techniques. Immediate transfer of embryos 
derived from superovulation resulted in 47 percent continuing to develop 
compared to 88 percent of the embryos left in situ (Rexroad and Powell, 
1991). Embryo survival after collection is no better when a complex me-
dium is used (Medium 199 plus 0.10 percent fetal bovine serum) than for 
a simple phosphate buffered saline with serum medium. Microinjection 
further reduces viability (Rexroad and Wall, 1987; Walton, etal. 1987) re-
sulting in approximately 12 percent of embryos surviving to lambing 
(Table 1).
Selection of embryos for transfer that were known to be viable and to 
have incorporated the transgene would reduce the costs associated with 
maintaining pools of recipients. Sheep embryos can be co-cultured for 
three days on oviductal cells with only about a 15 percent loss in viability if 
transferred to recipients that came into estrus 24 hours after the donors. 
Delayed recipients are necessary because co-culture somewhat retards 
embryonic development (Rexroad, etal, 1990). However, as the early 
cleavage divisions are largely programmed by maternal gene products, 
this does not allow an adequate test of the embryos long-term viability. 
Longer periods of co-culture are possible, but only modest results with re-
spect to long term development have been reported thus far (Gandolfi and 
Moor, 1987). If longer culture intervals of up to five to seven days can be 
reliably achieved, development in culture may become useful for predict-
ing long-term viability.
A further benefit of a longer culture period would be the ability to re-
move a few cells from an embryo and use PCR technology to ascertain 
whether or not the microinjected DNA had been incorporated into the 
embryo’s genome. Thus we would be in the position of transferring only 
those embryos to recipients that were known to be both viable and transgenic.
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Although there are at present a number of inefficiencies in the technol-
ogy used to produce transgenic livestock, they are likely to be overcome 
during this decade. However, the long-term application of this technology 
in animal agriculture is presently limited by our lack of knowledge about 
the genetic basis of rate-limiting steps that affect production traits. In 
most cases we do not know what genes to transfer in order to gain the 
maximum benefit to production efficiency.
GROWTH PROMOTING TRANSGENES TRANSFERRED INTO SHEEP
A number of fusion genes encoding growth promoting hormones have 
been transferred into sheep, including fusion genes encoding the human 
(Hammer, etal., 1985), bovine (Rexroad, etal., 1989) and ovine growth 
hormone (Ward, etal., 1988; Murray, et al, 1989) genes (GH) and the hu-
man growth hormone releasing factor (hGRF) (Rexroad, etal., 1989). A 
number of these transgenes have used the mouse metallothionein I 
(mMT) promoter. Other promoters used include the control sequences 
from the sheep metallothionein la (Mtla) gene (Ward, et al., 1988) and 
the mouse albumin and transferrin genes (Rexroad, etal., 1990).
These promoter elements were chosen in an attempt to direct the ex-
pression of the transgenes to specific organs, e.g. the liver, or to try to 
maintain a degree of external control over the level of expression of the 
transgenes. The mMT promoter had previously been shown to direct the 
expression of growth hormone to the liver, kidney and other organs in 
transgenic mice (Palmiter, et al. 1982,1983). The promoter elements of the 
various metallothionein genes can be stimulated to increase the level of 
expression of a linked coding region by the addition of heavy metals to the 
diet or drinking water. The mMt promoter had the disadvantage of being 
leaky, that is there was always sufficient expression of the growth hormone 
transgenes in the absence of heavy metal stimulation to promote growth 
of the mice to approximately 1.5X the size of non-transgenic littermates 
(Palmiter, etal., 1982,1983). However, in the absence of direct experimen-
tal evidence, the pattern of expression of the various mMT-GH and GRF 
transgenes in sheep could not be predicted.
The sheep Mtla promoter was selected by the Australian group for basi-
cally three reasons. First, ideally the expression of a transgene affecting 
growth should be under external control so that transgenic animals only 
express the transgene when it is economically advantageous to have them
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respond. Secondly, we thought that a more tightly controlled a transgene 
would be, the less likely to have adverse effects on the individuals carrying 
it. Thirdly, it was felt that transgenes composed entirely of sheep gene se-
quences would be more acceptable to lay persons, in particular consum-
ers. For these reasons, we elected to use the sheep Mtla promoter as it was 
known to have a lower basal level of expression than the mouse MT pro-
moter, while still retaining its heavy metal inducibility (Peterson and Mer-
cer, 1986).
The mouse albumin and transferrin promoters were selected to try to 
limit the expression of the transgenes to liver tissue in transgenic animals. 
These promoters were tried to attempt to limit the degree of undesirable 
side effects that had been observed in transgenic pigs carrying mMT based 
GH transgenes (Pursel, et al, 1987).
THE CONSEQUENCES OF GROWTH PROMOTING TRANSGENES EXPRESSION 
IN SHEEP
Thirty-six lambs have been produced by microinjecting fusion genes en-
coding either growth hormone or growth hormone releasing factor (Table 
1). Nine of these transgenic sheep carried transgenes that expressed high 
levels of growth hormone, while three lambs expressed growth hormone 
releasing factor. Many of the 24 non-expressing sheep have transmitted 
the transgene to their progeny, which also failed to express the transgene 
(Rexroad, etal., 1989,1990; Murray, etal., 1989; Nancarrow, et al, 1991).
The transgenic lambs expressing either GH or GRF grew at approxi-
mately the same rate as non-transgenic controls, even though they had 
circulating plasma GH levels from 3 to >1,000 times higher than found in 
control animals (Rexroad, etal, 1989; Murray, etal, 1989). The expressing 
transgenic animals also had elevated levels of circulating IGF-I and insu-
lin (Rexroad, et al, 1990; Nancarrow, et al, 1991). Additionally, we have 
observed that plasma levels of prolactin and the thyroid hormones were 
depressed in expressing females, but were elevated and not different from 
controls in a single expressing transgenic male. Lower levels of thyroid 
hormone are normally associated with a reduced basal metabolic rate 
(BMR), but in the case of two of the GH expressing females, BMR was in-
creased about 30 percent and metabolic heat production by 20-50 percent 
(Nancarrow, etal, 1991).
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The secretion of FSH and LH from the anterior pituitary gland was nor-
mal in both males and females, as were the serum levels of the sex steroids. 
However, both expressing males and females appear to have delayed 
sexual development when compared to controls (Nancarrow, etal., 1991). 
This is perhaps similar to the situation observed in expressing growth hor-
mone transgenic pigs where females remain anestrous and males lack li-
bido, but produce viable spermatozoa (Pursel, et al., 1990).
One of the goals of this research was to determine if GH transgenic 
sheep were more feed efficient and produced less fat than currently avail-
able animals, as has been observed in GH transgenic pigs (Pursel, etal., 
1989). Expressing transgenic sheep do not appear to have increased feed 
efficiency (Rexroad, et al., 1989), but they do have significantly reduced 
amounts of body fat (Ward, et al., 1990; Nancarrow, et al., 1991).
The continuously high levels of circulating growth hormone observed 
in the expressing transgenic sheep has led to severe health problems 
(Nancarrow, et al, 1991). None of the twelve expressing animals has at-
tained puberty, with all of them dying before one year of age. The cause of 
death has varied, but there are clear data that the over-expression of GH 
adversely affects liver, kidney and cardiac function (Nancarrow, et al., 
1991). Plasma levels of insulin and glucose are also abnormal, indicating 
an inability to maintain serum sugar levels that results in a diabetic condi-
tion (Rexroad, etal., 1990).
Although the efficiency of producing transgenic sheep is low, it is ap-
parent that foreign genes can be reliably transferred into sheep and ex-
pressed. The work with growth hormone transgenic sheep and pigs re-
ferred to here clearly shows that basic research is still required in a number 
of areas. The efficiency of the procedure needs to be improved to reduce 
the cost of producing genetically engineered animals.
More importantly, further work is required to identify promoter ele-
ments that, when used in transgene construction, will give a sufficient de-
gree of control over the tissue specificity, developmental timing and level 
of expression of the transgene. Clearly, the uncontrolled over-production 
of genes encoding hormones will mostly likely be detrimental to the ani-
mal as observed in these studies.
Although there is probably no limit on the types of genes that can be 
transferred into livestock species, further research is required to identify
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the genetic basis of the rate-limiting steps affecting economically impor-
tant traits. If genetic variation exists in a species that can positively affect 
the trait of interest, then selective breeding can be practiced. If variation 
does not exist and a gene from another species can be identified that will 
positively affect the trait, then gene transfer becomes the technique of 
choice. To date, there have only been a few candidate genes identified for 
transfer into livestock, such as the two genes of the cysteine biosynthetic 
pathway for wool production in sheep (Ward, et al, 1990), that can rea-
sonably be expected to significantly improve a production trait. The one 
exception may be for the dairy industry, where there are a number of po-
tential ways genetic engineering techniques maybe used to alter or im-
prove milk (Wilmut, et al., 1990).
FUTURE CONSIDERATIONS
The demonstration that genetic engineering techniques can be success-
fully applied to livestock animals raises a number of questions in such di-
verse areas as ethics and animal rights, economics and the future direc-
tions and applications of this research. As scientists involved in this work, 
we are satisfied that the information collected and the potential applica-
tions will be valuable to mankind. As our population increases and the 
resources of the Earth decrease, agricultural production must become 
more efficient. Does the non-scientist accept this point of view? Do we 
have the right to alter the genetics of our farm animals to increase produc-
tion efficiency, or for that matter, will the public accept the agricultural 
use of transgenic animals?
Apart from these questions on the morality and ethics of modifying a 
species’ genome, a number of other of questions remain to be answered. 
Who should pay for this research, which is clearly long-term and expen-
sive, and who will benefit? At present, most of the significant work has 
been carried out in laboratories with a high level of direct government 
funding, for example the USDA/ARS laboratory at Beltsville, Maryland or 
the CSIRO’s Division of Animal Production in Australia.
Transgenic experiments using livestock species requires long-term re-
search projects, in part due to the reproductive cycles of the animals and 
in part because of the need to carry out a careful examination of the con-
sequences of transgene expression in at least two or three generations of
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animals. Because the work is long-term with little or no prospect of early 
returns, only a few companies are currently prepared to contribute finan-
cially to this work. At a time when federal government granting agencies 
are experiencing a drop in the level of projects they can support, they are 
unwilling to commit support for the eight to ten years that these types of 
projects require.
It is not sufficient to conclude that the basic research should be done in 
less costly laboratory animals like the mouse and only scaled up to large 
animals after the transgene is proven. The Mtla-oGH transgene acts as a 
completely controllable gene in the mouse (Shanahan, et ah, 1989), yet was 
totally uncontrollable in transgenic sheep (Murray, etal, 1989). Further-
more, Mtla-oGH transgenic mice, when switched on, grow to about 1.5X 
larger than controls, are more feed efficient with respect to lean produc-
tion, deposit as much fat as controls (Pomp, etal, submitted) and do not 
suffer any apparent health problems. Thus, each transgene construct in-
tended for use in farm animals will ultimately need to be tried in farm ani-
mals during the research phase. It is only after the basic patterns of expres-
sion and consequences of a transgene’s expression have been assessed in a 
livestock species can valid predictions of the worth of that transgene to ag-
riculture be confidently made.
Thus, if this work is deemed important, who will pay for the research? 
Additionally, how will a suitable transgene be bred into the national 
herds? Who will control the flow of a valuable transgenic germplasm into 
the national herds? And how will this dissemination be paid for?
The production of transgenic animals also raises a number of legal or 
paralegal questions, both in the United States and in the international 
arena. For example, in the United States it is legal to patent a transgenic 
animal, but in Europe it is not. This raises a number of issues. How differ-
ent must two lines of transgenic animals be for separate patents to be is-
sued? How are patents on livestock going to be enforced in a loosely regu-
lated industry such as farming? What are the consequences in terms of in-
ternational trade?
The broad scientific questions are clear. We need to identify the rate 
limiting steps affecting production traits and appropriate genes that, 
when transferred, will overcome these limiting steps. In addition, we need 
to build up a library of tissue and developmentally specific promoter ele-
ments that can be used to drive the appropriate level of expression of a
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transgene. However, the societal answers to the questions we have raised 
here, and the setting of clear priorities and directions for the application of 
transgenic technology in animal agriculture have not yet been addressed.
REFERENCES
Costantini, F. and E. Lacy. 1981. Introduction of a rabbit beta globin gene into 
the mouse germ line. Nature, 294:92-94.
Gandolfi, F. and R. M. Moor. 1987. Stimulation of early embryonic-X-devel- 
opment in the sheep by co-culture with oviduct epithelial cells. J. 
Reprod. Fert. 81:23.
Gordon, J.W., G. A. Scangos, D.J. Plotkin, J. A. Barbosa and F. H. Ruddle. 
1980. Gentic transformation of mouse embryos by microinjection of 
purified DNA. Proc. Natl. Acad. Sci. USA 77:7380-7384.
Hammer, R.E., V. G. Pursel, C. E. Rexroad Jr., R. J. Wall, D. J. Bolt, K. M.
Ebert, R. D. Palmiter and R. L. Brinster. 1985. Production of transgenic 
rabbits, sheep and pigs by microinjection. Nature, 315:680-683.
Hogan, B., F. Costantini and E. Lacy. 1986. Manipulating the mouse embryo: A 
laboratory manual. Cold Spring Harbor Laboratory.
Murray, J.D., C. D. Nancarrow, J. T. Marshall, I. G. Hazelton and K. A. Ward. 
1989. Production of transgenic merino sheep by microinjection of 
ovine metallothionein-ovine growth hormone fusion genes. Reprod. 
Fert. Devel. 1:147-155.
Nancarrow, C.D., J. D. Murray, M. P. Boland, R. Sutton and I. G. Hazelton. 
1984. Effect of gonadotrophin releasing hormone in the production of 
single-cell embryos for pronuclear injection of foreign genes.in Repro-
duction in Sheep. D.R. Lindsay and D.T. Pearce eds. Aust. Acad. Sci., 
Canberra, pp. 286-288.
Nancarrow, C.D., J. D. Murray, M. P. Boland, I. G. Hazelton and R. Sutton. 
1984. Towards gene transfer into ruminant embryos: Effect of centrifu-
gation. Theriogenology 21: 248.
Nancarrow, C.D., J. T. A. Marshall, J. L. Clarkson, J. D. Murray, R. M. Millard, 
C. M. Shanahan, P.C. Wynn and K. A. Ward. 1991. Expression and 
physiology of performance regulating genes in transgenic sheep. /. 
Reprod. Fert., Suppl.43:277-29i.
Development of Growth Promoting Transgenes 261
R. D. Palmiter, R. L. Brinster, R. E. Hammer, M. E. Trumbauer, M. G.
Rosenfeld, N. C. Birnberg, and R. M. Evans.1982. Dramatic growth of 
mice that develop from eggs microinjected with metallothionein- 
growth hormone fusion genes. Nature, 300:611-615.
Palmiter, R.D., G. Norstedt, R. E. Gelinas, R. E. Hammer, and R. L. Brinster,. 
1983. Metallothionein-human GH fusion genes stimulate growth in 
mice. Science, 222:809-814.
Peterson, M.G. and J. F. B. Mercer. 1986. Structure and regulation of the sheep 
metallothionein-la gene. Eur. J. Biochem. 160:579-585.
Pomp, D., C. D. Nancarrow, K. A. Ward and J. D. Murray. Growth, feed effi-
ciency and body composition of transgenic mice expressing a sheep 
metallothionein la-sheep growth hormone fusion gene. Submitted 
manuscript Livestock Production Science (in press). 1992.
Pursel, V.G., C. E. Rexroad Jr, D. J. Bolt, K. F. Miller, R. J. Wall, R. E. Hammer, 
C. A. Pinkert, R. D. Palmiter andR. L. Brinster. 1987. Progress on gene 
transfer in farm animals. Vet. Immunology Immunopathology, 17:303-312.
Pursel, V.G., C. A. Pinkert, K. F. Miller, D. J. Bolt, R. G. Campbell, R. D.
Palmiter, R. L. Brinster and R. E. Hammer. i989.Genetic engineering of 
livestock. Science 244:1281-1288.
Pursel, V.G., R. E. Hammer, D. J. Bolt, R. D. Palmiter and R. L. Brinster. 1990. 
Integration, expression and germ-line transmission of growth-related 
genes in pigs. /. Reprod. Fert. Suppl. 41:77-87.
Rexroad, C.E. Jr. and A. M. Powell. 1991. Effect of serum-free co-culture and 
synchrony of recipients on development of cultured sheep embryos to 
fetuses. /. Animal Sci. 69:2066-2072.
Rexroad Jr, C.E. and V. G. Pursel. 1988. Status of gene transfer in domestic 
animals, nth Inter. Congr. on Animal Reprod. and A.I., Dublin. 5:28-35.
Rexroad, C.E. Jr. and R. J. Wall. 1987. Development of one-cell fertilized 
sheep ova following microinjection into pronuclei. Theriogenology 
27:611-619.
Rexroad, C.E. Jr., R. E. Hammer, D. J. Bolt, K. E. Mayo, L. A. Frohman, R. D. 
Palmiter and R. L. Brinster. 1989. Production of transgenic sheep with 
growth-regulating genes. Mol. Reprod.Devel. 1:164-169.
Rexroad, C.E. Jr., R. E. Hammer, R. R. Behringer, R. D. Palmiter and R L.
Brinster. 1990. Insertion, expression and physiology of growth-regulat-
ing genes in ruminants. /. Reprod.Fert. Suppl. 41:119-124.
262 Workshop White Papers
Rexroad, C.E. Jr., A. M. Powell, R. Rohan and R. J. Wall. 1990. Evaluation 
of co-culture as a method for selecting viable microinjected sheep 
embryos for transfer. Animal Biotech. 1:1-10.
Shanahan, C.M., N. W. Rigby, J. D. Murray, J. T. Marshall, C. A. Townrow, 
C. D. Nancarrow and K. A. Ward. Regulation of expression of a 
sheep metallothionein la-sheep growth hormone fusion gene in 
transgenic mice. Mol. Cell Biol. 9:5473-5479.
Simons, J.P., I. Wilmut, A. J. Clark, A. L. Archibald, J. O. Bishop and R.
Lathe. 1988. Gene transfer into sheep. Bio/Technology 6:179-183. 
Wagner, E.F., T. A. Stewart and B. Mintz. 1981. The human B-globin gene 
and a functional viral thymidine kinase in developing mice. Proc. 
Nat. Acad. Sci. USA 78:5016-5020.
Wagner, T.E., P. C. Hoppe, J. D. Jollick, D. R. Scholl, R. L. Hodinka and J.
B. Gault. 1981. Microinjection of the rabbit B-globin gene into zy-
gotes and its subsequent expression in adult mice and their off-
spring. Proc. Natl. Acad. Sci. USA 78:6376-6380.
Wall, R.J., V. G. Pursel, R. E. Hammer and R. L. Brinster. 1985. Develop-
ment of porcine ova that were centrifuged to permit visualization of 
pronuclei and nuclei. Biol. Reprod. 32:645-651.
Walton, J.R., J. D. Murray, J. T. Marshall and C. D. Nancarrow. 1987. Zy-
gote viability in gene transfer experiments. Biol.Reprod. 37:957-967. 
Ward, K.A., C. D. Nancarrow, J. D. Murray, C. M. Shanahan, C. R. Byrne, 
N. W. Rigby, C. A. Townrow, Z. Leish, B. W. Wilson, N. M.
Graham,P. C. Wynn, C. L. Hunt and P. A. Speck. 1990. The current 
status of genetic engineering in domestic animals. J. Dairy Sci. 
73:2586-2592.
Ward, K.A., J. D. Murray, C. M. Shanahan, N. W. Rigby and C. D.
Nancarrow. 1988. The creation of transgenic sheep for increased 
wool production in The Biology of Wool and Hair G.E. Rogers, P.J. 
Reis, K.A. Ward and R.M. Marshall eds. Chapman & Hall, London 
and New York. pp. 465-477.
Wilmut, I., A. L. Archibald, S. Harris, M. McClenaghan, J. P. Simons,
C. B. A. Whitelaw and A. J. Clark. 1990. Modification of milk compo-
sition./. Reprod. Fert. Suppl. 41:135-146.
Development of Growth Promoting Transgenes 263
